Anemia Drugs Change Black Box Warning
FDA Approves Revision to Warning Label for Procrit, Aranesp, and Epogen Anemia Drugs
Nov. 8, 2007 -- The FDA today approved revisions to a "black box" warning and other safety-related label changes for the anemia drugs Procrit, Aranesp, and Epogen.
Those drugs are erythropoiesis-stimulating agents (ESAs). They boost production of red blood cells.
The revisions expand labeling changes made in March 2007, which emphasize using the lowest possible dose of the drugs to avoid the need for a blood transfusion.
Highlights in the revised warning include:
"FDA strongly recommends that prescribers talk to their patients about the risks that ESAs might cause cancers to grow more quickly or shorten survival before they prescribe these drugs or continue ESA therapy. These risks should be weighed against the potential for red cell blood transfusion and their associated risks," the FDA's Richard Pazdur, MD, said in a news conference.
Pazdur directs the FDA's Office of Oncology Drug Products.
Procrit, Aranesp, and Epogen
ESAs are approved for treating certain cases of anemia, including in some cancer patients and people with chronic kidney failure.
Epogen and Procrit are also approved for use in certain anemia patients who are scheduled to undergo major surgery to reduce blood transfusions during or shortly after surgery and for the treatment of anemia caused by zidovudine (AZT) therapy in people with HIV, the virus that causes AIDS.
ESAs and Cancer
For cancer patients, the new boxed warnings emphasize that ESAs caused tumor growth and shortened survival in patients with advanced breast, head and neck, lymphoid, and non-small-cell lung cancer when they received a dose that attempted to achieve a hemoglobin level of 12 grams per deciliter (g/dL) or greater.
The boxed warnings also emphasize that no clinical data are available to determine whether there is a similar risk of shortened survival or increased tumor growth for cancer patients who receive an ESA dose that attempts to achieve a hemoglobin level of less than 12 g/dL. This is the hemoglobin level commonly achieved in clinical practice.